Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment

Eric Hollander, C. M. DeCaria, F. R. Schneier, H. A. Schneier, M. R. Liebowitz, D. F. Klein

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Seven patients who met DSM-III-R criteria for obsessive compulsive disorder and had only a partial response to the serotonin reuptake blockers fluoxetine, fluvoxamine, or clomipramine or were unable to tolerate therapeutic doses of these agents due to side effects underwent open treatment with fenfluramine augmentation. Fenfluramine is a serotonin releaser and reuptake blocker which is marketed as an anorectic agent. In doses of 20 to 60 mg/day, fenfluramine augmentation was well tolerated and resulted in a further decrease in obsessions and compulsions in six of these patients. Larger controlled studies are needed to confirm this finding.

Original languageEnglish (US)
Pages (from-to)119-123
Number of pages5
JournalJournal of Clinical Psychiatry
Volume51
Issue number3
StatePublished - 1990
Externally publishedYes

Fingerprint

Fenfluramine
Serotonin
Fluvoxamine
Obsessive Behavior
Clomipramine
Appetite Depressants
Fluoxetine
Obsessive-Compulsive Disorder
Diagnostic and Statistical Manual of Mental Disorders
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Hollander, E., DeCaria, C. M., Schneier, F. R., Schneier, H. A., Liebowitz, M. R., & Klein, D. F. (1990). Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. Journal of Clinical Psychiatry, 51(3), 119-123.

Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. / Hollander, Eric; DeCaria, C. M.; Schneier, F. R.; Schneier, H. A.; Liebowitz, M. R.; Klein, D. F.

In: Journal of Clinical Psychiatry, Vol. 51, No. 3, 1990, p. 119-123.

Research output: Contribution to journalArticle

Hollander, E, DeCaria, CM, Schneier, FR, Schneier, HA, Liebowitz, MR & Klein, DF 1990, 'Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment', Journal of Clinical Psychiatry, vol. 51, no. 3, pp. 119-123.
Hollander E, DeCaria CM, Schneier FR, Schneier HA, Liebowitz MR, Klein DF. Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. Journal of Clinical Psychiatry. 1990;51(3):119-123.
Hollander, Eric ; DeCaria, C. M. ; Schneier, F. R. ; Schneier, H. A. ; Liebowitz, M. R. ; Klein, D. F. / Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. In: Journal of Clinical Psychiatry. 1990 ; Vol. 51, No. 3. pp. 119-123.
@article{e28cfb82601f49858b447018b73f62ff,
title = "Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment",
abstract = "Seven patients who met DSM-III-R criteria for obsessive compulsive disorder and had only a partial response to the serotonin reuptake blockers fluoxetine, fluvoxamine, or clomipramine or were unable to tolerate therapeutic doses of these agents due to side effects underwent open treatment with fenfluramine augmentation. Fenfluramine is a serotonin releaser and reuptake blocker which is marketed as an anorectic agent. In doses of 20 to 60 mg/day, fenfluramine augmentation was well tolerated and resulted in a further decrease in obsessions and compulsions in six of these patients. Larger controlled studies are needed to confirm this finding.",
author = "Eric Hollander and DeCaria, {C. M.} and Schneier, {F. R.} and Schneier, {H. A.} and Liebowitz, {M. R.} and Klein, {D. F.}",
year = "1990",
language = "English (US)",
volume = "51",
pages = "119--123",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "3",

}

TY - JOUR

T1 - Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment

AU - Hollander, Eric

AU - DeCaria, C. M.

AU - Schneier, F. R.

AU - Schneier, H. A.

AU - Liebowitz, M. R.

AU - Klein, D. F.

PY - 1990

Y1 - 1990

N2 - Seven patients who met DSM-III-R criteria for obsessive compulsive disorder and had only a partial response to the serotonin reuptake blockers fluoxetine, fluvoxamine, or clomipramine or were unable to tolerate therapeutic doses of these agents due to side effects underwent open treatment with fenfluramine augmentation. Fenfluramine is a serotonin releaser and reuptake blocker which is marketed as an anorectic agent. In doses of 20 to 60 mg/day, fenfluramine augmentation was well tolerated and resulted in a further decrease in obsessions and compulsions in six of these patients. Larger controlled studies are needed to confirm this finding.

AB - Seven patients who met DSM-III-R criteria for obsessive compulsive disorder and had only a partial response to the serotonin reuptake blockers fluoxetine, fluvoxamine, or clomipramine or were unable to tolerate therapeutic doses of these agents due to side effects underwent open treatment with fenfluramine augmentation. Fenfluramine is a serotonin releaser and reuptake blocker which is marketed as an anorectic agent. In doses of 20 to 60 mg/day, fenfluramine augmentation was well tolerated and resulted in a further decrease in obsessions and compulsions in six of these patients. Larger controlled studies are needed to confirm this finding.

UR - http://www.scopus.com/inward/record.url?scp=0025240077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025240077&partnerID=8YFLogxK

M3 - Article

C2 - 2106515

AN - SCOPUS:0025240077

VL - 51

SP - 119

EP - 123

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 3

ER -